Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    24678979 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab (AMG 145) + background lipid lowering therapy;   Biological: Placebo + background lipid lowering therapy;   Drug: Atorvastatin 10 mg;   Drug: Atorvastatin 80 mg;   Drug: Atorvastatin 80 mg + Ezetimibe 10 mg;   Other: Diet Only (no drug)

Indicates status has not been verified in more than two years